Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern Territory

Joshua S Davis, Anuja C Kulatunga and Krispin Hajkowicz
Med J Aust 2013; 199 (1): 23. || doi: 10.5694/mja13.10083

To the Editor: Chronic hepatitis C virus (HCV) infection affects over 225 000 Australians1 and is a leading cause of the need for liver transplantation and of liver-related death, but curative treatments are available. Ethnicity is a major determinant of treatment responsiveness, with the lowest sustained virological response (SVR) rates reported in African patients, and the highest in Asian patients.2 Much of this difference is accounted for by racial differences in polymorphisms in the interleukin-28B (IL28B) gene;3 however, it is unknown how common these polymorphisms are in Indigenous Australians, and no studies have been published about hepatitis C treatment outcomes among Indigenous Australians.

Please login with your free MJA account to view this article in full

  • Joshua S Davis1
  • Anuja C Kulatunga2
  • Krispin Hajkowicz3

  • 1 Global and Tropical Health, Menzies School of Health Research, Darwin, NT.
  • 2 Karama Medical Centre, Darwin, NT.
  • 3 Royal Brisbane and Women’s Hospital, Brisbane, QLD.

Competing interests:

No relevant disclosures.

  • 1. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2012. Sydney: The Kirby Institute, the University of New South Wales, 2012.
  • 2. Muir AJ, Hu KQ, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011; 18: e134-e143.
  • 3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.